High levels of Lp(a) impact approximately 1 in 5 individuals globally, signaling an elevated risk of heart attacks, strokes, and valve disease. How should clinicians navigate this challenge, given the current lack of specific treatment options?

In this interview, Raul Santos MD, PhD, and Sun Moon Kim MD, FACC discuss strategies to lowering an elevated Lp(a) based on current evidence and available treatments.

Related References:

1. Virani, S. S., Koschinsky, M. L., Maher, L., Mehta, A., Orringer, C. E., Santos, R. D., Shapiro, M. D., & Saseen, J. J. (2022). Global think tank on the clinical considerations and management of lipoprotein(a): The top questions and answers regarding what clinicians need to know. Progress in cardiovascular diseases, 73, 32–40. https://doi.org/10.1016/j.pcad.2022.01.002
2. Rao, S., Jamal Siddiqi, T., Khan, M. S., Michos, E. D., Navar, A. M., Wang, T. J., Greene, S. J., Prabhakaran, D., Khera, A., & Pandey, A. (2022). Association of polypill therapy with cardiovascular outcomes, mortality, and adherence: A systematic review and meta-analysis of randomized controlled trials. Progress in cardiovascular diseases, 73, 48–55. https://doi.org/10.1016/j.pcad.2022.01.005